PMID- 23713483
OWN - NLM
STAT- MEDLINE
DCOM- 20141028
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 55
IP  - 3
DP  - 2014 Mar
TI  - Emerging issues after the recognition of in situ follicular lymphoma.
PG  - 482-90
LID - 10.3109/10428194.2013.807926 [doi]
AB  - This article reviews knowledge derived from the introduction of the concept of in 
      situ follicular lymphoma (FL). The following questions are addressed: (1) How 
      should in situ lymphomas be defined and diagnosed? (2) Is in situ lymphoma an 
      early step of lymphomagenesis? (3) Is the concept of early neoplasia applicable 
      to the lymphoma setting? (4) How should patients with in situ lymphoma be 
      managed? The commonly used term of in situ FL, also called FL in situ (FLIS), has 
      been adopted to define a B-cell lymphoid neoplasia with an intrafollicular growth 
      pattern. The neoplastic B cells are localized within the germinal center, without 
      invasion of surrounding structures. Pathological diagnosis requires recognizing 
      strong immunostaining of BCL2 and CD10 by neoplastic B cells inside the affected 
      follicles. Fluorescence in situ hybridization (FISH) analysis for t(14;18) is 
      mandatory in doubtful cases in which immunohistochemistry data are ambiguous. In 
      situ FL is probably the earliest stage of development of FL, while the concept of 
      "early" lymphoma is applicable when minimal disease extends beyond the boundaries 
      of the follicular compartment. From a clinical point of view, in situ FL has an 
      uncertain clinical behavior and unknown risk to progression to overt lymphoma. 
      How to approach and monitor patients with in situ FL is currently uncertain. An 
      asymptomatic patient with stage 1 in situ FL requires the same treatment plan as 
      an asymptomatic patient with stage 1 conventional FL. For patients with 
      concomitant overt malignancy, therapy must be applied according to the malignant 
      counterpart.
FAU - Carbone, Antonino
AU  - Carbone A
AD  - Department of Pathology, Centro di Riferimento Oncologico Aviano, Istituto 
      Nazionale Tumori, IRCCS , Aviano , Italy.
FAU - Gloghini, Annunziata
AU  - Gloghini A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130715
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - Carcinoma in Situ
MH  - Cell Transformation, Neoplastic/genetics
MH  - Germinal Center/pathology
MH  - Humans
MH  - Lymphoma, Follicular/diagnosis/*pathology
MH  - Neoplasm Staging
EDAT- 2013/05/30 06:00
MHDA- 2014/10/29 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/05/30 06:00 [entrez]
PHST- 2013/05/30 06:00 [pubmed]
PHST- 2014/10/29 06:00 [medline]
AID - 10.3109/10428194.2013.807926 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2014 Mar;55(3):482-90. doi: 10.3109/10428194.2013.807926. Epub 
      2013 Jul 15.